These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33138674)

  • 1. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Gaut D; Mead M
    Leuk Lymphoma; 2021 Jan; 62(1):8-31. PubMed ID: 33138674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.
    Wong ZC; Dillon LW; Hourigan CS
    Best Pract Res Clin Haematol; 2023 Jun; 36(2):101468. PubMed ID: 37353292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
    Araki D; Wood BL; Othus M; Radich JP; Halpern AB; Zhou Y; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
    J Clin Oncol; 2016 Feb; 34(4):329-36. PubMed ID: 26668349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
    Czyz A; Nagler A
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
    Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
    J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
    Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
    Núñez-Torrón Stock C; Jiménez Chillón C; Martín Moro F; Marquet Palomanes J; Velázquez Kennedy K; Piris Villaespesa M; Roldán Santiago E; Rodríguez Martín E; Chinea Rodríguez A; García Gutiérrez V; Moreno Jiménez G; López Jiménez J; Herrera Puente P
    Hematol Oncol; 2023 Oct; 41(4):753-761. PubMed ID: 37081742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
    Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
    Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Wang T; Zhou B; Zhang J; Zhang X; Liu T; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Lymphoma; 2021 Apr; 62(4):995-998. PubMed ID: 33191833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
    Percival ME; Wang HL; Zhang MJ; Saber W; de Lima M; Litzow M; Kebriaei P; Abdel-Azim H; Adekola K; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bejanyan N; Bhatt V; Byrne M; Cahn JY; Castillo P; Chao N; Chhabra S; Copelan E; Cutler C; DeFilipp Z; Dias A; Diaz MA; Estey E; Farhadfar N; Frangoul HA; Freytes CO; Gale RP; Ganguly S; Gowda L; Grunwald M; Hossain N; Kamble RT; Kanakry CG; Kansagra A; Kharfan-Dabaja MA; Krem M; Lazarus HM; Lee JW; Liesveld JL; Lin R; Liu H; McGuirk J; Munker R; Murthy HS; Nathan S; Nishihori T; Olsson RF; Palmisiano N; Passweg JR; Prestidge T; Ringdén O; Rizzieri DA; Rybka WB; Savoie ML; Schultz KR; Seo S; Sharma A; Solh M; Strair R; van der Poel M; Verdonck LF; Yared JA; Weisdorf D; Sandmaier BM
    Bone Marrow Transplant; 2021 Sep; 56(9):2108-2117. PubMed ID: 33864019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group.
    Selim A; Alvaro F; Cole CH; Fraser CJ; Mechinaud F; O'Brien TA; Shaw PJ; Tapp H; Teague L; Nivison-Smith I; Moore AS
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27812. PubMed ID: 31111633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
    Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
    Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.